Renal-Cell Carcinoma
By William King
NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Genitourinary Cancers, National Comprehensive Cancer Network (NCCN)
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors. Read More ›
By William King
The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD. Read More ›
In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma. Read More ›
In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib. Read More ›
Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved. Read More ›
Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment. Read More ›
The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab. Read More ›
In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy. Read More ›
Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability. Read More ›
Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch. Read More ›